- Report
- November 2024
- 258 Pages
Global
From €4279EUR$4,500USD£3,598GBP
- Report
- October 2024
- 181 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- March 2025
- 359 Pages
Global
From €5182EUR$5,450USD£4,357GBP
- Report
- March 2025
- 89 Pages
Global
From €5324EUR$5,600USD£4,477GBP
- Clinical Trials
- December 2024
- 180 Pages
Global
From €2377EUR$2,500USD£1,999GBP
- Clinical Trials
- December 2024
- 80 Pages
Global
From €1902EUR$2,000USD£1,599GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1902EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- October 2023
- 82 Pages
United Kingdom
From €3328EUR$3,500USD£2,798GBP
- Report
- February 2024
- 72 Pages
Global
From €3798EUR$3,995USD£3,194GBP
- Drug Pipelines
- February 2023
- 33 Pages
Global
From €9503EUR$9,995USD£7,991GBP
- Report
- November 2022
- 164 Pages
Global
From €3323EUR$3,495USD£2,794GBP
The Nsclc Therapeutics market is a subset of the larger Lung Cancer Drugs market. It focuses on the development of treatments for non-small cell lung cancer (NSCLC), the most common type of lung cancer. These treatments include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies are designed to target specific genetic mutations in cancer cells, while immunotherapies use the body's own immune system to fight cancer. Chemotherapy is a traditional form of cancer treatment that uses drugs to kill cancer cells.
The Nsclc Therapeutics market is highly competitive, with many companies developing treatments for NSCLC. Some of the major players in the market include AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, and Roche. Other companies such as AbbVie, Amgen, and Novartis are also active in the market. Show Less Read more
